Abstract
This 5-year follow-up of a phase 2 clinical trial assesses long-term durability of minimal residual disease–negative remission and time to disease progression among patients with newly diagnosed multiple myeloma who received triplet-based induction therapy with lenalidomide maintenance therapy.
Publication types
-
Clinical Trial, Phase II
-
Letter
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Dexamethasone / administration & dosage*
-
Dexamethasone / adverse effects
-
Drug Resistance, Neoplasm / drug effects
-
Female
-
Follow-Up Studies
-
Humans
-
Lenalidomide / administration & dosage*
-
Lenalidomide / adverse effects
-
Male
-
Middle Aged
-
Multiple Myeloma / diagnosis
-
Multiple Myeloma / drug therapy*
-
Multiple Myeloma / pathology
-
Neoadjuvant Therapy
-
Neoplasm Recurrence, Local / drug therapy
-
Neoplasm Recurrence, Local / pathology
-
Neoplasm, Residual
-
Oligopeptides / administration & dosage*
-
Oligopeptides / adverse effects
-
Progression-Free Survival
-
Remission Induction
-
Treatment Outcome
Substances
-
Oligopeptides
-
carfilzomib
-
Dexamethasone
-
Lenalidomide